Literature DB >> 6967897

Lymphocyte surface membrane immunoglobulin in myeloma. II. T cells with IgA-Fc receptors are markedly increased in mice with IgA plasmacytomas.

R G Hoover, R G Lynch.   

Abstract

BALB/c mice with established subcutaneous IgA plasmacytomas (MOPC-315, MOPC-167, McPC-603, or TEPC-15) develop large numbers of circulating theta-bearing lymphocytes that have surface membrane receptors for IgA. The extraordinary expansion of T alpha cells in mice with IgA plasmacytomas accounts for the large number of lymphocytes with surface membrane myeloma protein that are found in these mice. The IgA myeloma protein that was originally bound to the T cell receptor in vivo was competitively displaced in vitro by other purified IgA myeloma proteins but not by their F(ab)' fragments. After overnight incubation in vitro, or brief exposure to pronase, IgA was released from the T cell surface, rendering available a surface membrane receptor for IgA. In vitro binding of purified IgA to the T alpha cell receptor was not inhibited by purified IgG1 or IgM myeloma proteins. T alpha cells were not increased in mice with three variant plasmacytomas that did not secrete large amounts of IgA. These observations: i) establish the generality of T alpha cell expansion in mice with IgA plasmacytomas, ii) establish an association between elevated serum IgA levels and T alpha cell expansion, and iii) identify a source of large numbers of T alpha cells that can be specifically purified for structural and functional studies.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6967897

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  15 in total

Review 1.  Rous-Whipple Award lecture. The biology and pathology of lymphocyte Fc receptors.

Authors:  R G Lynch
Journal:  Am J Pathol       Date:  1998-03       Impact factor: 4.307

Review 2.  Regulation of IgA synthesis and immune response by T cells and interleukins.

Authors:  J R McGhee; J Mestecky; C O Elson; H Kiyono
Journal:  J Clin Immunol       Date:  1989-05       Impact factor: 8.317

Review 3.  Contrasuppression in the mucosal immune system.

Authors:  H Kiyono; D R Green; J R McGhee
Journal:  Immunol Res       Date:  1988       Impact factor: 2.829

4.  Isotype regulation of antibody production: T-cell hybrids can be selectively induced to produce IgG1 and IgG2 subclass-specific suppressive immunoglobulin-binding factors.

Authors:  I Löwy; C Brezin; C Neauport-Sautes; J Theze; W H Fridman
Journal:  Proc Natl Acad Sci U S A       Date:  1983-04       Impact factor: 11.205

Review 5.  Characteristics and function of Fc receptors on human lymphocytes.

Authors:  P M Lydyard; M W Fanger
Journal:  Immunology       Date:  1982-09       Impact factor: 7.397

Review 6.  Sensitivity of receptors for IgA on T560, a murine B lymphoma, to phorbol myristate acetate and to phosphatidylinositol-specific phospholipase C.

Authors:  J M Phillips-Quagliata; T D Rao; A A Maghazachi; A González; A M Faria
Journal:  Immunol Res       Date:  1991       Impact factor: 2.829

7.  Increase of lymphocytes with Fc receptors for IgE in patients with allergic rhinitis during the grass pollen season.

Authors:  H L Spiegelberg; R A Simon
Journal:  J Clin Invest       Date:  1981-10       Impact factor: 14.808

8.  Expansion of Fc receptor-bearing T lymphocytes in patients with immunoglobulin G and immunoglobulin A myeloma.

Authors:  R G Hoover; S Hickman; H M Gebel; N Rebbe; R G Lynch
Journal:  J Clin Invest       Date:  1981-01       Impact factor: 14.808

9.  Induction of Fc receptors for IgA on murine T cell hybridoma by human monoclonal IgA and by high molecular weight IgA in IgA nephropathy.

Authors:  A Chevailler; R C Monteiro; M Daëron; P Lesavre
Journal:  Clin Exp Immunol       Date:  1987-01       Impact factor: 4.330

10.  Correlation between soluble serum CD16 (sCD16) levels and disease stage in patients with multiple myeloma.

Authors:  C Mathiot; J L Teillaud; M Elmalek; V Mosseri; L Euller-Ziegler; A Daragon; B Grosbois; J L Michaux; T Facon; J F Bernard
Journal:  J Clin Immunol       Date:  1993-01       Impact factor: 8.317

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.